Trial · NCT06764485
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Radiographic progression-free survival (rPFS) by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (soft tissue) and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (bone) criteria | Up to 4 years | |
| Secondary | Overall Survival (OS) | Up to 4 years | |
| Secondary | Recommended dose of BMS-986365 for Part 2 | Up to approximately 1.5 years | |
| Secondary | Progression-free survival (PFS) | Up to 4 years | |
| Secondary | Confirmed overall response rate (ORR) by BICR assessment in participants with measurable disease using RECIST 1.1 (soft tissue) and PCWG3 (bone) criteria | Up to 4 years | |
| Secondary | Time to pain progression (TTPP) | Up to 4 years | |
| Secondary | Time to symptomatic progression (TTSP) | Up to 4 years | |
| Secondary | Time to initiation of the first subsequent systemic therapy (TFST) | Up to 4 years | |
| Secondary | Prostate-specific antigen (PSA) response rate | Up to 4 years | |
| Secondary | Change from baseline in Functional Assessment of Cancer Therapy - Prostate Cancer (FACT-P) total scores | Up to 4 years | |
| Secondary | Change from baseline in Prostate Cancer Subscale (PCS) scores | Up to 4 years | |
| Secondary | Change from baseline in trial outcome index (TOI) | Up to 4 years | |
| Secondary | Change from baseline in Brief Pain Inventory - Short Form (BPI-SF) worst pain (item #3) intensity | Up to 4 years | |
| Secondary | Incidence of adverse events (AEs) | Up to 4 years | |
| Secondary | Incidence of serious adverse events (SAEs) | Up to 4 years | |
| Secondary | Incidence of AEs leading to dose modifications | Up to 4 years | |
| Secondary | Incidence of AEs leading to interruptions | Up to 4 years | |
| Secondary | Incidence of AEs leading to discontinuation | Up to 4 years | |
| Secondary | Electrocardiogram (ECG) findings | Up to 4 years | ECG Findings defined as : * Number of Postbaseline Abnormal Corrected QT (QTc) Values * Number of abnormal Beats Per Minute (BPM) |
| Secondary | Incidence of laboratory abnormalities | Up to 4 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06764485/registered